These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31743620)

  • 41. Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children.
    Chiappini E; Lisi C; Giacomet V; Erba P; Bernardi S; Zangari P; Di Biagio A; Taramasso L; Giaquinto C; Rampon O; Gabiano C; Garazzino S; Tagliabue C; Esposito S; Bruzzese E; Badolato R; Zanaboni D; Cellini M; Dedoni M; Mazza A; Pession A; Giannini AM; Salvini F; Dodi I; Carloni I; Cazzato S; Tovo PA; de Martino M; Galli L;
    BMC Infect Dis; 2022 Jan; 22(1):55. PubMed ID: 35033018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BREATHER (PENTA 16) short-cycle therapy (SCT) (5 days on/2 days off) in young people with chronic human immunodeficiency virus infection: an open, randomised, parallel-group Phase II/III trial.
    Butler K; Inshaw J; Ford D; Bernays S; Scott K; Kenny J; Klein N; Turkova A; Harper L; Nastouli E; Paparini S; Choudhury R; Rhodes T; Babiker A; Gibb D
    Health Technol Assess; 2016 Jun; 20(49):1-108. PubMed ID: 27377073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors associated with human immunodeficiency virus-1 low-level viremia and its impact on virological and immunological outcomes: A retrospective cohort study in Beijing, China.
    Bai R; Lv S; Hua W; Su B; Wang S; Shao Y; Li Z; Liu A; Sun L; Dai L
    HIV Med; 2022 Mar; 23 Suppl 1():72-83. PubMed ID: 35293102
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
    Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
    Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
    Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Viremia copy-years predicts mortality among treatment-naive HIV-infected patients initiating antiretroviral therapy.
    Mugavero MJ; Napravnik S; Cole SR; Eron JJ; Lau B; Crane HM; Kitahata MM; Willig JH; Moore RD; Deeks SG; Saag MS;
    Clin Infect Dis; 2011 Nov; 53(9):927-35. PubMed ID: 21890751
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.
    Han Y; Li Y; Xie J; Qiu Z; Li Y; Song X; Zhu T; Li T
    PLoS One; 2015; 10(3):e0120705. PubMed ID: 25821963
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART.
    Vancoillie L; Mortier V; Demecheleer E; Schauvliege M; Vandekerckhove L; Vogelaers D; Verhofstede C
    Antivir Ther; 2015; 20(8):789-94. PubMed ID: 25945956
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa.
    Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP
    Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Very low level viraemia and risk of virological failure in treated HIV-1-infected patients.
    Teira R; Vidal F; Muñoz-Sánchez P; Geijo P; Viciana P; Ribera E; Domingo P; Castaño M; Martínez E; Roca B; Puig T; Estrada V; Deig E; Galindo MJ; de la Fuente B; Lozano F; Montero M; Muñoz-Sanz A; Sanchez T; Terrón A; Romero-Palacios A; Lacalle JR; Garrido M; Suárez-Lozano I;
    HIV Med; 2017 Mar; 18(3):196-203. PubMed ID: 27476742
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Renal dysfunction by baseline CD4 cell count in a cohort of adults starting antiretroviral treatment regardless of CD4 count in the HIV Prevention Trials Network 071 [HPTN 071; Population Effect of Antiretroviral Therapy to Reduce HIV Transmission (PopART)] study in South Africa.
    Bock P; Nel K; Fatti G; Sloot R; Ford N; Voget J; Gunst C; Grobbelaar N; Louis F; Floyd S; Hayes R; Ayles H; Beyers N; Fidler S;
    HIV Med; 2019 Jul; 20(6):392-403. PubMed ID: 30963667
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Viral suppression among children and their caregivers living with HIV in western Kenya.
    Humphrey JM; Genberg BL; Keter A; Musick B; Apondi E; Gardner A; Hogan JW; Wools-Kaloustian K
    J Int AIDS Soc; 2019 Apr; 22(4):e25272. PubMed ID: 30983148
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
    Cooper DA; Cordery DV; Zajdenverg R; Ruxrungtham K; Arastéh K; Bergmann F; Neto JL; Scherer J; Chaves RL; Robinson P;
    PLoS One; 2016; 11(1):e0144917. PubMed ID: 26730818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort.
    Scarsi KK; Eisen G; Darin KM; Meloni ST; Rawizza HE; Tchetgen Tchetgen EJ; Agbaji OO; Onwujekwe DI; Gashau W; Nkado R; Okonkwo P; Murphy RL; Kanki PJ;
    Clin Infect Dis; 2016 Feb; 62(4):512-8. PubMed ID: 26561532
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Viraemia before, during and after pregnancy in HIV-infected women on antiretroviral therapy in rural KwaZulu-Natal, South Africa, 2010-2015.
    Chetty T; Newell ML; Thorne C; Coutsoudis A
    Trop Med Int Health; 2018 Jan; 23(1):79-91. PubMed ID: 29121445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
    Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
    AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.